ArticlePloS one2026
Inhibitory effects of mycosubtilin on proliferation of colon cancer SW480 cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of novel and effective natural anti-cancer drugs represents a significant focus in contemporary biomedical research. Mycosubtilin (Myco), a cyclic lipopeptide produced by Bacillus subtilis, has not previously been investigated for its potential anti-colorectal cancer activity. This study employed a comprehensive approach combining network pharmacology, molecular docking, cellular analysis, flow cytometry single-color staining, and western blot analysis to preliminarily investigate the potential molecular mechanisms underlying Myco's anti-CRC activity. Findings revealed that Myco significantly outperformed 5-Fluorouracil (5-FU) in inhibiting SW480 cell proliferation. Myco effectively triggered apoptosis. This was supported by the typical apoptotic morphological features, including nuclear condensation and fragmentation. Concurrently, Myco treatment downregulated the expression of the anti-apoptotic protein, Bcl-2. These findings suggest that Myco has potential application value in inhibiting the proliferation of human colorectal cancer SW480 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.